U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07217158) titled 'Role of ROS and cAMP-PKA Biomarkers in ADPKD' on Oct. 13.
Brief Summary: The primary objective is to determine the prognostic value of markers of ROS and cAMP-PKA signaling to assess disease severity and progression in patients with ADPKD.
Study Start Date: July 01, 2023
Study Type: OBSERVATIONAL
Condition:
Autosomal Dominant Polycystic Kidney Disease
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Mayo Clinic
Information provided by (Responsible Party): Maria V. Irazabal Mira, Mayo Clinic
Disclaimer: Curated by HT Syndication....